Beware of False “Cures” for Autism
What you need to know
Unapproved and Potentially Harmful Products
Autism Spectrum Disorder (ASD) affects about 1 in 68 children, and while early behavioral therapies can help improve symptoms, there is no cure for autism. Unfortunately, some companies promote unproven products that falsely claim to treat or even cure ASD — and some can be dangerous.
What the FDA Wants You to Know
The FDA has acted against companies marketing unapproved and potentially harmful products that claim to treat autism. These include:
- Chelation Therapies (sprays, drops, baths): Meant to remove “toxins,” but can dangerously deplete essential minerals.
- Hyperbaric Oxygen Chambers: Only approved for specific medical uses — not autism.
- Detoxifying Clay Baths: Claim to “pull out toxins” through the skin — no evidence they help.
- MMS (chlorine dioxide), raw camel milk, essential oils, and others: Heavily marketed, not scientifically proven, and can pose real health risks.
FDA-Approved Treatments Exist — But Only for Specific Symptoms
There are two FDA-approved medications to manage irritability associated with autism:
- Risperidone (ages 5–16)
- Aripiprazole (ages 6–17)
These medications help with specific symptoms — not autism itself — and should only be used under medical supervision.
Real Help for ASD
- Early behavioral interventions can improve communication and daily living skills.
- Treatment should be tailored to the individual’s needs.
- Work with licensed healthcare professionals, not unregulated products.
Watch Out for These Red Flags
- “Quick fixes” or “miracle cures”
- Claims to treat a wide range of unrelated conditions
- Personal stories with no scientific backing
- Secret ingredients or “breakthrough science”
If it sounds too good to be true, it probably is.
If you have questions about therapies or treatments, talk to a doctor who specializes in autism. Trust science — not sales pitches.
Sterile Drug Manufacturing Violations at Daewoo Pharmaceutical
FDA Cracks Down on Sterile Drug Manufacturing Violations The U.S. Food and Drug Administration (FDA) has issued a warning letter to Daewoo Pharmaceutical Co., Ltd. in Busan, South Korea, citing serious and widespread violations of current Good Manufacturing Practices...
The FDA Orphan Drug Program
Incentives for Rare Disease Drug Development The FDA’s Orphan Drug Program was established to encourage the development of drugs for rare diseases that affect fewer than 200,000 people in the U.S. Because these diseases often lack market incentives due to small...
FDA Alert: Abiomed Impella Blood Pump Controller
Abiomed Impella blood pump controllers Controller May Fail to Detect Device Abiomed has issued an urgent safety notice for its Automated Impella Controller (AIC) due to a potentially serious issue where the system may fail to detect the Impella blood pump when...